NL-OMON53529招募中不适用
Does the hematopoietic stem cell govern residual inflammatory cardiovascular risk in type 2 diabetes? - DOTAFLAME
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Age >50 years old
- •- Diagnosed with type 2 diabetes
- •- HbA1c >64mmol/mol
排除标准
- •1. (History of) malignant diseases or any clinically significant medical
- •condition that could interfere with the conduct of the study in the opinion of
- •the investigator.
- •2. Chronic or recent infections and/or clinical signs of infection and/or a
- •plasma C-reactive protein above 10ng/ml
- •3. Auto-immune diseases (including type 1 diabetes)
- •4. Recent or chronic immunosuppressant or antibiotic usage
- •5. Use of any GLP1R-agonist at baseline or prior intolerance to use of
- •GLP1R-agonists.
- •6. Inability or unwillingness to comply with the protocol requirements, or
- •deemed by investigator to be unfit for the study.
- •7. Uncontrolled hypertension (systolic blood pressure > 180mmHg, diastolic
- •blood pressure > 100mmHg)
- •8. Uncontrolled chronic inflammatory conditions, including gout.
- •9. Women of childbearing age who are not using effective contraceptives.
- •10. Heart failure New York Heart Association (NYHA) class IV at screening visit.
- •11. Active liver disease or hepatic dysfunction, defined as aspartate
- •aminotransferase (ASAT) or alanine aminotransferase (ALAT) >= 2 times the upper
- •limit of normal (ULN) at screening visit.
- •12. Pancreatitis in medical history.
研究者
相似试验
已完成
不适用
Indication and outcome of hematopoietic stem cell transplantation in primary immunodeficiency with predominant hypogammaglobulinemia – a retrospective studyDRKS00004296Centrum für Chronische Immundefizienz (CCI), Universitätsklinikum Freiburg31
招募中
不适用
Are circulating hematopoietic stem and progenitor cells a potential biomarker for therapy response and disease progression in patients with squamous cell carcinoma of the head and neck?NL-OMON46829Antoni van Leeuwenhoek Ziekenhuis30
已完成
不适用
Indication of allogenic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in first remission: Retrospective analysisAdults with philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in first remissionJPRN-UMIN000016287Chiba Aoba Municipal Hospital100
进行中（未招募）
1 期
Randomized study with stem cell transplantation versus standard treatment with alemtuzumab, cladribine or ocrelizumab in patients with relapsing remitting multiple sclerosis.EUCTR2017-001362-25-SEHelse Bergen HF, Haukeland University Hospital100
进行中（未招募）
1 期
Randomized study with stem cell transplantation versus standard treatment with alemtuzumab, cladribine or ocrelizumab in patients with relapsing remitting multiple sclerosis.Relapsing remitting multiple sclerosis.MedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-001362-25-NLHelse Bergen HF, Haukeland University Hospital100